4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Financings

4D Molecular Therapeutics, Inc.

Financings

RaiseDate
Public offering of equity
Closed: US$93M raised · US$10.51 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Evercore ISI (co-lead), Cantor (co-lead), RBC Capital Markets
Use of proceeds: Fund planned operations into 2H 2028, including a planned 4D-150 Phase 3 trial in diabetic macular edema
Nov 10, 2025
Strategic investment of 4DMT equity
Tranche closed: US$7.5M raised
Buyers: Cystic Fibrosis Foundation (up to $11 million in 4DMT equity in two tranches; first tranche of $7.5 million closed)
Use of proceeds: Accelerate development of 4D-710 for cystic fibrosis: second dosing in Phase 1, advancement into Phase 2, and Phase 3 readiness
Oct 13, 2025

Read by 6ix AI from the company's releases